Bruce Strober, MD/PhD, FAAD
About
Research
Publications
2024
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Armstrong A, Soliman A, Gisondi P, Fang S, Patel M, Strober B. Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology And Therapy 2024, 1-11. PMID: 39453596, DOI: 10.1007/s13555-024-01293-y.Peer-Reviewed Original ResearchDermatology Life Quality IndexSkin clearanceIndirect comparisonsStatic Physician's Global AssessmentRisankizumab-treated patientsPhysician global assessmentTreatment of psoriasisMatching-adjusted indirect comparisonIndividual patient dataLife Quality IndexPlaque psoriasisPsoriasis AreaRisankizumabDeucravacitinibNew therapiesIntroductionDespite advancesPsO.Global assessmentQuality of lifePsoriasisPatientsPropensity scorePatient dataClearanceHealthcare providers54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Langley R, Fiorentino D, Bagel J, Lafferty K, Skobelev E, Langholff W, Lebwohl M, Ho V, Strober B. 54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2024, 91: ab61. DOI: 10.1016/j.jaad.2024.07.252.Peer-Reviewed Original Research52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon K, Thaçi D, Gooderham M, Okubo Y, Strober B, Peterson L, Deherder D, Pinto J, Gisondi P. 52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials. Journal Of The American Academy Of Dermatology 2024, 91: ab145. DOI: 10.1016/j.jaad.2024.07.577.Peer-Reviewed Original Research51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per Dermatology Life Quality Index scores: Data from the Effisayil 2 trial
Gottlieb A, Strober B, Kokolakis G, Merola J, Zheng M, Langley R, Tang M, Hofmann P, Thoma C, Warren R. 51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per Dermatology Life Quality Index scores: Data from the Effisayil 2 trial. Journal Of The American Academy Of Dermatology 2024, 91: ab316. DOI: 10.1016/j.jaad.2024.07.1256.Peer-Reviewed Original Research52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA
Sicco K, Soung J, Strober B, Irvine A, Wajsbrot D, Gromek K, Wolk R, Barnes D, Takiya L. 52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA. Journal Of The American Academy Of Dermatology 2024, 91: ab55. DOI: 10.1016/j.jaad.2024.07.228.Peer-Reviewed Original Research54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Strober B, Augustin M, Tada Y, Lafferty K, Skobelev E, Langholff W, Fakharzadeh S, Gniadecki R. 54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2024, 91: ab152. DOI: 10.1016/j.jaad.2024.07.605.Peer-Reviewed Original Research51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Callis-Duffin K, Sima A, Eckmann T, Beeghly A, Photowala H, Patel M, Garg V, Strober B. 51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2024, 91: ab59. DOI: 10.1016/j.jaad.2024.07.244.Peer-Reviewed Original Research52284 Influence of Biological Sex on Clinical Manifestation in Moderate-to-Severe Atopic Dermatitis and on Dupilumab Treatment Effectiveness
Zink A, Beck L, Lebwohl M, Gooderham M, Strober B, Maul J, Pinter A, Johansson E, Chen Z, Hagen S, Bastian M. 52284 Influence of Biological Sex on Clinical Manifestation in Moderate-to-Severe Atopic Dermatitis and on Dupilumab Treatment Effectiveness. Journal Of The American Academy Of Dermatology 2024, 91: ab240. DOI: 10.1016/j.jaad.2024.07.952.Peer-Reviewed Original Research50857 Treatment Discontinuation Patterns in Patients With Psoriasis Receiving Apremilast in North America: A Registry-Based Analysis
Strober B, Zhong Y, Varga S, Napoli A, Sima A, Beeghly A, Zhuo J. 50857 Treatment Discontinuation Patterns in Patients With Psoriasis Receiving Apremilast in North America: A Registry-Based Analysis. Journal Of The American Academy Of Dermatology 2024, 91: ab93. DOI: 10.1016/j.jaad.2024.07.377.Peer-Reviewed Original Research51099 Real-world application of the International Psoriasis Council guidelines for prescribing systemic treatment to patients with psoriasis in North America
Strober B, Zhong Y, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. 51099 Real-world application of the International Psoriasis Council guidelines for prescribing systemic treatment to patients with psoriasis in North America. Journal Of The American Academy Of Dermatology 2024, 91: ab293. DOI: 10.1016/j.jaad.2024.07.1164.Peer-Reviewed Original Research